Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

US Previously Marketed

2

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Adrenergic receptor alpha-2

2

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

2

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

1952

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Dental care

2

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Secondary

2

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Non-penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

2

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

CAS

2

EPA CompTox

2

EVMPD

2

FDA UNII

2

NCI_THESAURUS

2

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

1

Salts, Hydrates, Esters, etc.

1

All Match

Any Match

Exclude Selected

Exclude Selected

Showing 1 - 2 of 2 results

First page disabled
Previous page disabled
1
Next page disabled
Next page disabled

LEVONORDEFRIN

V008L6478D

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1952

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor alpha-2

Conditions:

Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. It is administered in a pre-mixed solution with local anesthetics, such as mepivacaine or procaine.

LEVONORDEFRIN HYDROCHLORIDE

U63S13UAOR

Export Data
Search for Structure

Status:

US Previously Marketed

First approved in 1952

Class (Stereo):

CHEMICAL (ABSOLUTE)

Targets:

Adrenergic receptor alpha-2

Conditions:

Levonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry. It is administered in a pre-mixed solution with local anesthetics, such as mepivacaine or procaine.

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1